HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Roundup: Keep Extra-Strength Acetaminophen OTC – McNeil-Backed Survey

This article was originally published in The Tan Sheet

Executive Summary

Keep extra-strength acetaminophen OTC – McNeil-backed survey; direct sellers Jenuesse, MonaVie combine; Four Elements makes drug claims; and more news in brief.

You may also be interested in...



In Brief

Lane Labs in contempt, judge says; NAD delineates between “entire” and “100%”; ERSP eyes stem cell claims; Probiotics lift Schiff brands; more news In Brief.

McNeil Proposes Tylenol Label Change To Keep 1,000-MG Dose Available OTC

In a bid to keep 500-mg tablets and 1,000-mg doses of acetaminophen available over the counter, McNeil Consumer Healthcare argues revised dosing instructions would address the root cause of unintentional overdose without unduly restricting access to the popular painkiller

Outlook 2023: Market Experts On Importance Of Value, Mental Health In A ‘World On Fire’

Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS133912

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel